The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-microemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.

The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.

A medicine for improving the state of pregnancy, which contains a compound of general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine:

##STR00001##

A medicine for improving the state of pregnancy, which contains a compound of general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine:

##STR00001##

Methods of diagnosing and treating pathologic hypogonadotropic hypogonadism and reproductive endocrine dysfunction using kisspeptin and kisspeptin analogs.

The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

The present invention provides a compound or a pharmaceutically acceptable salt, isomer, prodrug, polymorph or solvate thereof, and a preparation method therefor and use thereof. The compound provided in the present invention has comparable or superior activity to Elagolix as a GnRHR antagonist in calcium flux assays and have better pharmacokinetic properties.

The present invention relates to pharmaceutical compositions having improved stability.

The present disclosure relates to the technical field of biology, and in particular to a Macrobrachium nipponense Cathepsin L gene and use of dsRNA thereof, including the Macrobrachium nipponense Cathepsin L gene, a gene fragment and the dsRNA thereof, and use of the dsRNA in inhibiting ovary development of Macrobrachium nipponense. The Macrobrachium nipponense Cathepsin L gene is obtained at first with the full-length nucleotide sequence as shown in SEQ ID No. 1 and the amino acid sequence as shown in SEQ ID No. 2. Gene fragments with sequences of SEQ ID No. 3 and SEQ ID No. 8 are obtained by using technologies such as RNA interference, and dsRNA1 and dsRNA2 are synthesized from the two gene fragments. The synthesized dsRNA1 and dsRNA2 are injected into a pericardial cavity of a female Macrobrachium nipponense and the result shows that the dsRNA1 can effectively slow down the ovary development speed of the female Macrobrachium nipponense.